The effect of intravitreal ranibizumab on systemic hypertension in age-related macular degeneration patients with hypertension.

The effect of intravitreal ranibizumab on systemic hypertension in age-related macular degeneration patients with hypertension. - The effect of intravitreal ranibizumab on systemic hypertension in age-related macular degeneration patients with hypertension.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013240

Enrollment

Registered

2014-02-27

Start date

2014-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with age related macular degeneration and hypertension (systolic blood pressure of >140mmHg and diastolic blood pressure of >90mmHg at baseline measurement), planned to receive treatment with intravitreal ranibizumab at Tokushima University Hospital.

Exclusion criteria

Exclusion criteria: Patients refused entry into the study.

Design outcomes

Primary

Measure	Time frame
systemic blood pressure	—

Countries

Japan

Contacts

Public ContactTakashi Katome

Institute of Health Biosciences, The University of Tokushima Graduate School Department of Ophthalmology

katome@tokushima-u.ac.jp088-633-7163

Outcome results